ANZUP trials – kidney
ANZUP is currently running a number of kidney cancer trials. For more details information about these trials, go to the ANZUP kidney cancer trials web page: https://anzup.org.au/clinical-trials/kidney-cancer-trials/
KEYPAD ANZUP 1601 Status: Open & recruiting Location: Australia wide Activated sites: 15
The most common kind of advanced kidney cancer is called clear cell kidney cancer. This trial aims to improve survival rates for people with this cancer.
Patients recruited: 51 • Patients required: 70
Renal cell carcinoma (RCC) is the 7th most diagnosed cancer in Australia and the 14th most common cancer in Western populations. Approximately 90% of kidney cancers are renal cell carcinomas (RCC). At the moment the five-year survival rate for Australians diagnosed with kidney cancer is 78.5%, although most people with kidney cancer localised only to the kidney can be cured.
ANZUP collaborates with the University of Sydney through the NHMRC CTC to conduct the KEYPAD Trial.
Immune therapies have been shown to be effective in about a quarter of patients with clear cell renal cell carcinoma after the standard treatment (sunitinib or pazopanib) has failed.
NSW • Calvary Mater Newcastle • Northern Cancer Institute • Concord Repatriation General Hospital • St George Hospital • Border Medical Oncology Research Unit • St Vincent’s Hospital Sydney
This study will test if denosumab, a drug frequently used to treat osteoporosis, (thinning of the bones), can team up with immune therapy to improve survival and increase the chance of the cancer shrinking for people with clear cell kidney cancer. In the trial, people with advanced clear cell kidney cancer will be offered treatment with two antibodies (a type of protein). This trial will investigate if these drugs taken together can increase the ability of the body’s immune system to attack kidney cancer cells. It is hoped that by combining pembrolizumab with denosumab, will stimulate the immune system, so that the immune therapy will work better in the tumours.
We thank and acknowledge Amgen and MSD for providing product and funding to support our KEYPAD Trial. We are currently running the KEYPAD trial at the following locations:
QLD • Royal Brisbane & Women’s Hospital • Sunshine Coast University Hospital • Icon Cancer Care • The Townsville Hospital SA • Flinders Medical Centre VIC • Eastern Health • Monash Health Clayton • Ballarat Oncology and Haematology Services WA • Fiona Stanley Hospital
A LITTLE BELOW THE BELT 51
